Erudio Healtherudio.com
Sponsor
Gilead Sciences trials: what clinicians said in public
An HCP commentary report on 1 clinical trial sponsored by Gilead Sciences: iMMagine-3. It covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 22 more trials with public commentary and no report yet.
Listed by lead sponsor as registered on ClinicalTrials.gov (Gilead Sciences; Kite, A Gilead Company). A trial led by a partner or a research group is on that sponsor's page. Only trials with public clinician commentary found are listed, not every trial the sponsor runs.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| iMMagine-3 NCT06413498 · Kite, A Gilead Company | relapsed/refractory multiple myeloma | Phase 3 | 159 | 24 | Standard | Nov 14, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| ASCENT-04 NCT05382286 · Gilead Sciences DeepView → | PD-L1-positive previously untreated advanced triple-negative breast cancer | Phase 3 | Deep | View | |||
| ASCENT-03 NCT05382299 · Gilead Sciences DeepView → | previously untreated advanced triple-negative breast cancer | Phase 3 | Deep | View | |||
| ZUMA-1 NCT02348216 · Kite, A Gilead Company DeepView → | refractory large B-cell lymphoma | Phase 1/Phase 2 | Deep | View | |||
| TROPiCS-02 NCT03901339 · Gilead Sciences DeepView → | HR+/HER2- metastatic breast cancer | Phase 3 | Deep | View | |||
| TROPHY-U-01 NCT03547973 · Gilead Sciences DeepView → | unresectable locally advanced or metastatic urothelial cancer | Phase 2 | Deep | View | |||
| EVOKE-01 NCT05089734 · Gilead Sciences DeepView → | previously treated advanced or metastatic NSCLC | Phase 3 | Deep | View | |||
| TROPiCS-04 NCT04527991 · Gilead Sciences DeepView → | locally advanced or metastatic unresectable urothelial cancer | Phase 3 | Deep | View | |||
| ASCENT-07 NCT05840211 · Gilead Sciences DeepView → | HR+/HER2- locally advanced or metastatic breast cancer | Phase 3 | Deep | View | |||
| iMMagine-1 NCT05396885 · Kite, A Gilead Company DeepView → | relapsed or refractory multiple myeloma | Phase 2 | Deep | View | |||
| ZUMA-12 NCT03761056 · Kite, A Gilead Company DeepView → | first-line high-risk large B-cell lymphoma | Phase 2 | Deep | View | |||
| ZUMA-3 NCT02614066 · Kite, A Gilead Company DeepView → | adult relapsed/refractory B-precursor acute lymphoblastic leukemia | Phase 1/Phase 2 | Deep | View | |||
| ZUMA-23 NCT05605899 · Kite, A Gilead Company DeepView → | first-line high-risk large B-cell lymphoma | Phase 3 | Deep | View | |||
| EVOKE-02 NCT05186974 · Gilead Sciences DeepView → | first-line advanced/metastatic NSCLC without actionable genomic alterations | Phase 2 | Deep | View | |||
| TROPiCS-03 NCT03964727 · Gilead Sciences DeepView → | metastatic solid tumors | Phase 2 | Deep | View | |||
| ENHANCE-2 NCT04778397 · Gilead Sciences DeepView → | previously untreated TP53-mutated acute myeloid leukemia | Phase 3 | Deep | View | |||
| ENHANCE-3 NCT05079230 · Gilead Sciences DeepView → | newly diagnosed AML ineligible for intensive chemotherapy | Phase 3 | Deep | View | |||
| ZUMA-22 NCT05371093 · Kite, A Gilead Company DeepView → | relapsed/refractory follicular lymphoma | Phase 3 | Deep | View | |||
| IMMU-132-01 NCT01631552 · Gilead Sciences StandardView → | epithelial cancer | Phase 1/Phase 2 | Standard | View | |||
| ZUMA-7 NCT03391466 · Kite, A Gilead Company StandardView → | second-line relapsed/refractory diffuse large B-cell lymphoma | Phase 3 | Standard | View | |||
| NCT05633654 NCT05633654 · Gilead Sciences FocusedView → | Not given | Phase 3 | Focused | View | |||
| PALISADES-1 NCT04989803 · Kite, A Gilead Company FocusedView → | relapsed and/or refractory B-cell lymphoma | Phase 1/Phase 2 | Focused | View | |||
| EVOKE-SCLC-04 NCT06801834 · Gilead Sciences FocusedView → | previously treated extensive stage small cell lung cancer | Phase 3 | Focused | View | |||